LustGarden Foundation for Pancreatic Cancer Research

Pancreatic Cancer Research

As the largest private funder of pancreatic cancer research, we are relentlessly focused on improving patient outcomes and we are making progress every day. Thanks to separate funding to support administrative expenses, 100 percent of every donation goes directly to research.

Navigating Pancreatic Cancer

We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.

Patient Checklist

Checklist

August 1, 2018 ladmin

As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]

Research

Clinical Trials Finder

July 30, 2018 ladmin

If you have been diagnosed with pancreatic cancer, a clinical trial may be your best treatment option. Many clinical trials are underway for patients in all stages of the disease and may involve new combinations of currently available drugs or new drugs that have worked in other cancers. No matter where you are in your journey, we encourage you to learn more about clinical trials.

Lets Win! Pancreatic Cancer

Let’s Win! Pancreatic Cancer

July 20, 2018 ladmin

LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]

Pancreatic Cancer Connections

July 7, 2018 ladmin

Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery.

Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

Lustgarten News

View All Articles

Holiday
Rock & Roll Bash

Join us on Decemer 3rd for a night of holiday fun – dancing, delicious food and drinks, and an exclusive performance by the world-famous Radio City Rockettes.

The Madison Square Garden Company and AMC Networks host the Holiday Rock & Roll Bash to benefit the Lustgarten Foundation. To date, this fabulous event has raised more than $24 million for pancreatic cancer research.

The Lustgarten Foundation is America’s largest private foundation dedicated to funding pancreatic cancer research. Based in Woodbury, NY, the Foundation supports research to find a cure for pancreatic cancer.

Learn More

Navigating Pancreatic Cancer

A Guide for Patients & Caregivers

Receive Your Free Copy

Patients and caregivers can also request a free hard copy of this book at contactus@lustgarten.org.  Please write book request in the subject line and provide your name, mailing address, telephone number and email address.

Download a free copy of Navigating Pancreatic Cancer: A Guide for Patients and Caregivers

Download Your Copy Now

Our updated Navigating Pancreatic Cancer: A Guide for Patients & Caregivers handbook is here! Thanks to an educational grant from Celgene and support from Ipsen Pharmaceuticals, this handbook is a valuable resource and roadmap for patients and caregivers faced with a pancreatic cancer diagnosis. Part One addresses immediate needs, including a checklist for newly diagnosed patients; guidance on making treatment decisions; surgery; drug treatments; clinical trials; use of complementary and alternative methods; supportive care; coping; and caring for a loved one.

Part 2 offers background information about the disease and its causes, signs and symptoms, and diagnosis.

We hope this guide will empower patients and caregivers to ask bold questions, seek out cutting-edge treatments, and confront the unique challenges of pancreatic cancer head-on, armed with all of the knowledge needed to make informed decisions.

Bulk orders are available to professionals only. For additional copies to share with colleagues or patients, please fill in our book order form. The books are free, but we do charge $20 per carton of books for shipping and handling. Each carton contains 40 books.

At Lustgarten, we are making progress every day in our fight against pancreatic cancer. Our commitment to everyone impacted by pancreatic cancer has never been stronger, and we will continue to fund research until a cure is found. We believe it’s no longer a matter of “if” we are going to conquer this disease. It’s a matter of when.

Download Your Copy Now

Related Topics

View our blog series.
Learn how you can get involved.
Find an event in your community.

 

Learn More

Possible drug target for pancreatitis

 Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually. Patients who suffer from hereditary pancreatitis have a 40 to 50 percent lifetime risk of developing pancreatic cancer. Dannielle Engle, a former Cold Spring Harbor Laboratory (CSHL) Cancer Center postdoctoral fellow who was recently appointed Assistant Professor at Salk Institute, studies the progression of pancreatitis to pancreatic cancer. She has focused on a potentially powerful biomarker, a chemical structure created by complex sugar molecules called CA19-9, since CA19-9 is elevated in patients with pancreatitis and pancreatic cancer.

Learn More

Pancreatic Cancer News

View All Articles

Yale scientists help immune system find hidden cancer cells

14. 10. 19 ladmin

Cancer cells are masters at avoiding detection, but a new system developed by Yale scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology. The new system reduced or eliminated […]

Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

8. 10. 19 ladmin

 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled 100 patients in its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500). The multicenter, open-label, randomized trial is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®️ (devimistat) in […]

Study: Innovative pancreatic cancer treatment may rev up immune system

8. 10. 19 ladmin

A University of Rochester Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away. The result is that the combination […]

Cancer Is Still Beating Us—We Need a New Start

4. 10. 19 ladmin

I have been studying and treating cancer for 35 years, and here’s what I know about the progress made in that time: There has been far less than it appears. Despite some advances, the treatments for most kinds of cancer continue to be too painful, too damaging, too expensive and too ineffective. The same three […]

Response rate to albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b/2 pilot clinical tria

3. 10. 19 ladmin

 Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in conjunction with the Pancreatic Cancer Research Team and Cancer Research And Biostatistics. Published […]

Drug Trio Improves Odds Against Advanced Pancreatic Cancer

3. 10. 19 ladmin

A three-drug chemo cocktail appears to shrink tumors and improve survivorship among pancreatic cancer patients, a new, small study shows. Tumors substantially shrank for just over 71% of patients treated with a three-drug regimen of nab-paclitaxel, gemcitabine and platinum-based cisplatin, the researchers found. Further, 16 patients (64%) out of the 25 treated were still alive […]

Fungal Invasion of Pancreas Creates Cancer Risk

2. 10. 19 ladmin

Certain fungi move from the gut to the pancreas, expand their population more than a thousand-fold, and encourage pancreatic cancer growth, a new study finds. Published online in Nature October 2, the study is the first to offer strong evidence that the mycobiome—the local mix of fungal species in the pancreas—can trigger changes that turn normal cells into pancreatic […]

Why Can’t We Stop Pancreatic Cancer?

23. 9. 19 ladmin

Pancreatic cancer, which will be diagnosed in about 56,770 people in the United States this year, is the only cancer with a rising mortality rate through 2014, although five-year survival has begun to inch up, from 8 percent to 9 percent by 2016. It remains the nation’s third leading cause of cancer deaths, after cancers […]

A compound may improve pancreatic cancer survival rate, scientists find

19. 9. 19 ladmin

Scientists have discovered a compound could help slow down pancreatic cancer by targeting proteins that promote metastatic cells. Researchers at Johns Hopkins Medicine found that the compound, 4-HAP, reduced tumors in mice and could improve survival for pancreatic cancer patients. According to the National Cancer Institute, 73,554 people in the U.S. have pancreatic cancer and […]

Join Us

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top